{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Jimenez N"],"funding":["Instituto de Salud Carlos III","Jansen"],"pagination":["4757"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9564355"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["14(19)"],"pubmed_abstract":["(1) Background: Androgen deprivation therapy (ADT) and docetaxel (DX) combination is a standard therapy for metastatic hormone-sensitive prostate cancer (mHSPC) patients. (2) Methods: We investigate if tumor transcriptomic analysis predicts mHSPC evolution in a multicenter retrospective biomarker study. A customized panel of 184 genes was tested in mRNA from tumor samples by the nCounter platform in 125 mHSPC patients treated with ADT+DX. Gene expression was correlated with castration-resistant prostate cancer-free survival (CRPC-FS) and overall survival (OS). (3) Results: High expression of androgen receptor (AR) signature was independently associated with longer CRPC-FS (hazard ratio (HR) 0.6, 95% confidence interval (CI) 0.3-0.9; <i>p =</i> 0.015), high expression of estrogen receptor (ESR) signature with longer CRPC-FS (HR 0.6, 95% CI 0.4-0.9; <i>p =</i> 0.019) and OS (HR 0.5, 95% CI 0.2-0.9, <i>p =</i> 0.024), and lower expression of tumor suppressor genes (TSG) (<i>RB1</i>, <i>PTEN</i> and <i>TP53</i>) with shorter OS (HR 2, 95% CI 1-3.8; <i>p =</i> 0.044). <i>ARV7</i> expression was independently associated with shorter CRPC-FS (HR 1.5, 95% CI 1.1-2.1, <i>p =</i> 0.008) and OS (HR 1.8, 95% CI 1.2-2.6, <i>p =</i> 0.004), high <i>ESR2</i> was associated with longer OS (HR 0.5, 95% CI 0.2-1, <i>p =</i> 0.048) and low expression of <i>RB1</i> was independently associated with shorter OS (HR 1.9, 95% CI 1.1-3.2, <i>p =</i> 0.014). (4) Conclusions: AR, ESR, and TSG expression signatures, as well as <i>ARV7</i>, <i>RB1,</i> and <i>ESR2</i> expression, have a prognostic value in mHSPC patients treated with ADT+DX."],"journal":["Cancers"],"pubmed_title":["Transcriptional Profile Associated with Clinical Outcomes in Metastatic Hormone-Sensitive Prostate Cancer Treated with Androgen Deprivation and Docetaxel."],"pmcid":["PMC9564355"],"funding_grant_id":["PI18/714","212082PCR4056"],"pubmed_authors":["Climent MA","Gonzalez-Billalabeitia E","Rodriguez-Carunchio L","Prat A","Ferrer-Mileo L","Garcia-Esteve S","Mellado B","Cros S","Reig O","Figols M","Garcia de Herreros M","Aversa C","Jimenez Peralta D","Font A","Rodriguez-Vida A","Ribal MJ","Jimenez N","Chirivella I","Marin-Aguilera M","Domenech M"],"additional_accession":[]},"is_claimable":false,"name":"Transcriptional Profile Associated with Clinical Outcomes in Metastatic Hormone-Sensitive Prostate Cancer Treated with Androgen Deprivation and Docetaxel.","description":"(1) Background: Androgen deprivation therapy (ADT) and docetaxel (DX) combination is a standard therapy for metastatic hormone-sensitive prostate cancer (mHSPC) patients. (2) Methods: We investigate if tumor transcriptomic analysis predicts mHSPC evolution in a multicenter retrospective biomarker study. A customized panel of 184 genes was tested in mRNA from tumor samples by the nCounter platform in 125 mHSPC patients treated with ADT+DX. Gene expression was correlated with castration-resistant prostate cancer-free survival (CRPC-FS) and overall survival (OS). (3) Results: High expression of androgen receptor (AR) signature was independently associated with longer CRPC-FS (hazard ratio (HR) 0.6, 95% confidence interval (CI) 0.3-0.9; <i>p =</i> 0.015), high expression of estrogen receptor (ESR) signature with longer CRPC-FS (HR 0.6, 95% CI 0.4-0.9; <i>p =</i> 0.019) and OS (HR 0.5, 95% CI 0.2-0.9, <i>p =</i> 0.024), and lower expression of tumor suppressor genes (TSG) (<i>RB1</i>, <i>PTEN</i> and <i>TP53</i>) with shorter OS (HR 2, 95% CI 1-3.8; <i>p =</i> 0.044). <i>ARV7</i> expression was independently associated with shorter CRPC-FS (HR 1.5, 95% CI 1.1-2.1, <i>p =</i> 0.008) and OS (HR 1.8, 95% CI 1.2-2.6, <i>p =</i> 0.004), high <i>ESR2</i> was associated with longer OS (HR 0.5, 95% CI 0.2-1, <i>p =</i> 0.048) and low expression of <i>RB1</i> was independently associated with shorter OS (HR 1.9, 95% CI 1.1-3.2, <i>p =</i> 0.014). (4) Conclusions: AR, ESR, and TSG expression signatures, as well as <i>ARV7</i>, <i>RB1,</i> and <i>ESR2</i> expression, have a prognostic value in mHSPC patients treated with ADT+DX.","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Sep","modification":"2025-04-19T13:25:13.626Z","creation":"2025-04-19T13:25:13.626Z"},"accession":"S-EPMC9564355","cross_references":{"pubmed":["36230681"],"doi":["10.3390/cancers14194757"]}}